Related Experiment Video
Updated: Feb 8, 2026
Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels
Published on: December 13, 2024
Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials
Jan A Staessen1, Ji-Guang Wang, Lutgarde Thijs
1Study Coordinating Centre, Department of Molecular and Cardiovascular Research, University of Leuven, Belgium. jan.staessen@med.kuleuven.ac.be
Insights
Calcium channel blockers effectively treat isolated systolic hypertension in older adults, reducing cardiovascular risks. Blood pressure lowering largely explains trial outcomes, emphasizing tight blood pressure control for better patient prognosis.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Hypertension management in older adults requires evaluating drug efficacy and safety.
- Calcium channel blockers (CCBs) represent a newer class of antihypertensive agents.
- Understanding the extent to which blood pressure reduction influences clinical outcomes is crucial.
Purpose of the Study:
- To summarize findings from the Syst-Eur Trial on CCB treatment in elderly patients.
- To review large trials comparing older and newer antihypertensive drug classes.
- To update meta-regression analyses on blood pressure lowering's role in trial outcomes.
Main Methods:
- Analysis of Syst-Eur Trial data for older patients with isolated systolic hypertension.
- Pooled evidence review from nine actively controlled outcome trials (62,605 patients).
- Meta-regression analysis of 30 trials (149,407 patients) examining blood pressure gradients.
Main Results:
- CCB treatment in Syst-Eur reduced stroke and cardiovascular complications in older adults.
- CCB treatment improved diabetic patient prognosis, reduced proteinuria, and prevented dementia.
- Pooled trials confirmed CCBs' long-term efficacy and safety comparable to older drug classes.
- CCBs showed similar overall cardiovascular benefit versus diuretics/beta-blockers, with potential for greater stroke protection.
- Meta-regression indicated blood pressure lowering largely explains outcome differences across trials.
- No evidence suggested ACE inhibitors or alpha-blockers offer benefits beyond blood pressure reduction.
Conclusions:
- Drug treatment for isolated systolic hypertension in older adults, particularly with CCBs, is beneficial.
- Calcium channel blockers are effective and safe alternatives to older antihypertensive classes.
- Tight blood pressure control is paramount for improving patient outcomes in hypertension management.
Abstract:
This article has three purposes: 1) to summarize recent findings of the Syst-Eur Trial; 2) to provide a short overview of the large trials in hypertension that have compared older with newer drug classes; and 3) to update the results of a meta-regression analysis that addressed the question of: to what extent blood pressure (BP) lowering can explain the findings of recent outcome trials in hypertensive patients or high-risk patients with normotension or hypertension. The Syst-Eur trial showed that in older patients with isolated systolic hypertension, drug treatment starting with a dihydropyridine calcium channel blocker reduced the risk of stroke and of all cardiovascular complications. Furthermore, this treatment regimen improved the prognosis of diabetic patients; reduced the incidence of proteinuria; and prevented dementia, in particular Alzheimer's disease. The pooled evidence from nine recently published actively controlled outcome trials involving 62,605 hypertensive patients proved that calcium channel blockers have the same long-term efficacy and safety as the older drug classes. Compared with diuretics and beta-blockers, calcium channel blockers may offer greater protection against stroke and less protection against myocardial infarction, resulting in similar overall cardiovascular benefit. A meta-regression analysis including 30 trials and 149,407 hypertensive or high-risk patients showed that BP gradients largely accounted for most-if not all-of the differences in outcome. These findings emphasize the desirability of tight BP control. The hypothesis that angiotensin converting enzyme inhibitors or alpha-blockers might influence outcome beyond their BP lowering-effects was not confirmed.
Related Concept Videos
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
02:55The Evidence for Evolution
01:12Statistical Software for Data Analysis and Clinical Trials
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...